# OM336 in Seropositive Autoimmune Diseases

> **NCT07229144** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Ouro Medicines** · enrollment: 39 (estimated)

## Conditions studied

- Sjogrens Disease
- Idiopathic Inflammatory Myopathy (IIM)

## Interventions

- **DRUG:** OM336

## Key facts

- **NCT ID:** NCT07229144
- **Lead sponsor:** Ouro Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11
- **Primary completion:** 2027-06
- **Final completion:** 2028-03
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07229144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07229144, "OM336 in Seropositive Autoimmune Diseases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07229144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*